Mobia Medical reported second quarter 2026 revenue of $13.5 million, a 102% increase from the prior year period, driven by higher adoption of its Vivistim System. The company achieved an 83.2% gross margin and incurred a net loss of $21.0 million, or $1.10 per share, compared to a $10.5 million loss in the previous year. Operating expenses rose 83% to $29.2 million due to increased commercial personnel costs and development spending. The filing notes the completion of an initial public offering that raised approximately $134.0 million in net proceeds, bringing cash and equivalents to $177.1 million as of June 30, 2026. Additionally, two-year follow-up data for its VNS-REHAB therapy was published in Neurology®, demonstrating durable improvements in motor function. The company provided full year 2026 revenue guidance between $54.0 million and $56.0 million. Mobia Medical is a medical device company developing implantable vagus nerve stimulation solutions for stroke recovery.

On July 30, 2026, Mobia Medical, Inc. expanded its Board of Directors from seven to eight members by appointing Myriam J. Curet, M.D., as a Class II director with a term expiring at the 2028 annual meeting. Dr. Curet is recognized as an independent director under SEC and Nasdaq standards and previously served as Executive Vice President and Chief Medical Officer of Intuitive Surgical, Inc., retiring in March 2026 after a tenure beginning in December 2005. She also holds faculty positions at Stanford University School of Medicine and serves on the boards of Inspire Medical Systems, Inc. and Stereotaxis, Inc. The company operates in the medical technology industry.

Mobia Medical, Inc. expanded its Board of Directors from six to seven members by appointing Reza Zadno, Ph.D. as a Class III director. Dr. Zadno will also serve on the Compensation Committee, replacing Dr. William Harrington, who resigned from that committee. Mobia Medical, Inc. is a medical technology company.